Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
Deutsche Gesellschaft für Chirotherapie und Osteopathie e. V.
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
Asklepios Kliniken GmbH & Co. KGaA
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
LTS Lohmann Therapie-Systeme AG
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. With the acquisition, Renaissance facilities will become ...
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
Asklepios Kliniken GmbH & Co. KGaA
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Europäischer Rechnungshof - European Court of Auditors
Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...
Europäischer Rechnungshof - European Court of Auditors
Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...
Europäischer Rechnungshof - European Court of Auditors
Voiko EU löytää parannuskeinon lääkepulaan? - Tiedotustilaisuus verkossa keskiviikkona 17. syyskuuta klo 10.00 Keski-Euroopan kesäaikaa - Kertomus julkaistaan samana päivänä klo 17.00 Keski-Euroopan kesäaikaa Euroopan tilintarkastustuomioistuin kutsuu teidät ...
Europäischer Rechnungshof - European Court of Auditors
Kan EU afhjælpe kritiske mangler på lægemidler? - Online pressebriefing: onsdag den 17. september kl. 10.00 CEST - Offentliggørelse: samme dag kl. 17.00 CEST Den Europæiske Revisionsret inviterer til online pressebriefing vedrørende sin kommende særberetning om EU's foranstaltninger til at sikre tilgængelighed af lægemidler ...
Europäischer Rechnungshof - European Court of Auditors
Can the EU cure critical medicine shortages? - Online press briefing: Wednesday 17 September at 10.00 a.m. CEST - Publication: Same day at 5.00 p.m. CEST The European Court of Auditors (ECA) would like to invite you to an online press briefing on its upcoming special report on EU measures to ensure the availability of medicines – ...
Europäischer Rechnungshof - European Court of Auditors
Czy UE rozwiąże problem krytycznych niedoborów leków? - Spotkanie informacyjne online – środa 17 września o godz. 10.00 CEST - Publikacja – tego samego dnia o godz. 17.00 Europejski Trybunał Obrachunkowy serdecznie zaprasza na spotkanie informacyjne online dla prasy ...
Asklepios Kliniken GmbH & Co. KGaA
Hamburg (ots) - - With a million euros, it is one of the world’s most highly endowed awards for medical research The nomination period for the Broermann Medical Innovation Award 2026 has begun. Endowed with a million euros, this international award is among the most prestigious honors for medical research worldwide. Scientists from around the globe who have made ...
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...
Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...
